You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Onglyza Articles
Popular Onglyza Articles
Highly Recommended Onglyza Articles
Send a link to this page to your friends and colleagues.
Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor produced by AstraZeneca and Bristol-Myers Squibb, has been approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
So what exactly are DPP-4 inhibitors, and how do they help people with type 2 diabetes? DPP-4 inhibitors, like Januvia and now Onglyza, stabilize blood glucose levels by increasing insulin production and decreasing glucose production. As their name would suggest, they manage this by inhibiting DPP-4. When DPP-4 is its usual uninhibited self, it breaks down incretins, which are a group of hormones in the gastrointestinal system. Conversely, when DPP-4 is inhibited, the level of incretins rises. A higher level of incretins is a good thing. Why? Because incretins increase the release of insulin into the blood after a meal even before glucose levels rise, and inhibit the release of glucagon, a hormone that is produced by the pancreas when blood glucose is low. Inhibiting the release of glucagon is also a good thing. Again, why? Because glucagon raises the level of glucose in the blood by causing the liver to convert glycogen to glucose.
Let's put it another way; inhibiting DPP-4 increases incretins, which decrease glucagon release, and increases insulin which then decreases glucose. Make sense? Now say it three times fast. Now say it backwards.
For a more detailed explanation of DPP-4 inhibitors and incretins, read The Incretin Saga: Mimetics, Enhancers, and Inhibitors.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.